Granules India has entered into an agreement with Hubei Biocause Heilen Pharmaceutical Co., Joint Venture Partner for sale of 33,000,000 equity shares of 1 RMB each fully paid-up held by the Company in Granules-Biocause Pharmaceutical for a consideration of RMB 109 million.
Conclusion of this transaction is subject to fulfilment of certain closing conditions as well as applicable regulatory approvals.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
